{"filings":[{"id":722996,"accession_number":"0001035267-26-000042","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-05-28T20:35:49+00:00","items":["5.02","9.01"],"status":"ready","headline":"Intuitive Surgical names Taylor Patton CCO, Henry Charlton moves to SVP Global Business Ops","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taylor Patton promoted to Chief Commercial and Marketing Officer, effective July 1, 2026.","Henry Charlton transitions to SVP of Global Business Operations after serving as CCO.","Patton previously led Intuitive's Ion platform launch as Global SVP of Endoluminal.","Charlton has been with Intuitive since 2003; will support smooth transition.","Patton joins Executive Leadership team; Charlton will focus on global value generation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90740,"accession_number":"0001035267-26-000035","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-05-04T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical boosts buyback to $5.0B; shareholders approve plan amendment","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board increased stock repurchase authorization to $5.0B aggregate, including prior remaining balance.","Stockholders approved amendment to 2010 Incentive Award Plan, increasing authorized shares by 5M to 125.35M.","All 10 director nominees were elected at annual meeting; each received over 273M votes for.","Advisory say-on-pay passed with ~93.3% support (265M for, 17M against).","PricewaterhouseCoopers ratified as independent auditor for FY 2026 with ~98.6% of votes cast."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":90739,"accession_number":"0001035267-26-000029","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-04-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q1 rev $2.77B (+23%), EPS $2.50 non-GAAP; procedures +17%, da Vinci placements 431","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.77B (+23% YoY); GAAP EPS $2.28, non-GAAP EPS $2.50 (vs. $1.92/$1.81 prior year).","Worldwide procedures +17% YoY; da Vinci +16%, Ion +39%.","Placed 431 da Vinci systems (vs 367), including 232 da Vinci 5 (vs 147); installed base 11,395 (+12%).","Repurchased 2.3M shares for $1.1B in Q1; cash and investments $7.98B (down $1.05B).","FY2026 guidance: da Vinci procedure growth 13.5%-15.5%; non-GAAP gross margin 67.5%-68.5% (incl. 1% tariff impact)."],"consensus_eps_estimate":null,"consensus_eps_actual":2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":2770800000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100505,"accession_number":"0001035267-26-000012","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-03-02T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Intuitive Surgical completes acquisition of European distributors, expands direct ops in 5 countries","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquisition closed March 1, 2026, of da Vinci and Ion distribution business from ab medica, Abex, Excelencia Robótica.","Direct operations begin in Italy, Spain, Portugal, Malta, and San Marino.","Approximately 250 employees join Intuitive's European team.","Combined installed base >470 da Vinci surgical systems in those countries as of Dec 31, 2025.","Ion endoluminal system launched in Italy and Spain."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100504,"accession_number":"0001035267-26-000006","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-01-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 revenue $2.87B (+19% YoY); non-GAAP EPS $2.53 vs $2.21; 2026 procedure growth guidance 13-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $2.87B (+19% YoY); GAAP net income $795M ($2.21 diluted EPS); non-GAAP net income $914M ($2.53 diluted EPS).","Worldwide da Vinci procedures +17%, Ion procedures +44% YoY; placed 532 da Vinci systems (303 da Vinci 5) and 42 Ion systems.","Installed base: 11,106 da Vinci systems (+12% YoY); 995 Ion systems (+24% YoY).","2026 outlook: da Vinci procedure growth 13-15%; non-GAAP gross margin 67-68% (includes ~1.2% tariff headwind).","Q4 included $70M contribution to Intuitive Foundation (vs $45M in Q4 2024)."],"consensus_eps_estimate":null,"consensus_eps_actual":7.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":10064700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":100503,"accession_number":"0001035267-26-000003","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q4 2025 revenue $2.87B, up 19% YoY; procedures grow 18%","summary_kind":"llm","event_type":"earnings","confidence":"medium","bullets":["Revenue $2.87B in Q4 (+19% YoY); full year $10.06B (+21%).","Worldwide da Vinci procedures +17% in Q4, +18% full year; Ion procedures +44% Q4, +51% FY.","Placed 532 da Vinci systems in Q4 (+8% YoY), including 303 da Vinci 5 systems (up from 174).","2026 da Vinci procedure growth guidance 13-15%.","Full year da Vinci procedures exceeded 3.15 million; U.S. general surgery +18%."],"consensus_eps_estimate":null,"consensus_eps_actual":7.87,"consensus_revenue_estimate":null,"consensus_revenue_actual":10064700000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116828,"accession_number":"0001035267-25-000211","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intuitive Surgical CDO Brian Miller transitions to Head of Digital and AI Strategy effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Brian E. Miller, Ph.D., will cease serving as Chief Digital Officer effective January 1, 2026.","He will assume a new role as Head of Digital and AI Strategy, no longer reporting to CEO.","Miller remains employed by Intuitive Surgical in a reduced executive capacity.","No replacement for CDO announced; the role appears to be eliminated."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":116827,"accession_number":"0001035267-25-000206","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-10-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 revenue $2.51B (+23% YoY); EPS $1.95 GAAP / $2.40 non-GAAP; procedures +20%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Worldwide procedures grew ~20% YoY; da Vinci +19%, Ion +52%.","Revenue $2.51B (+23% YoY); GAAP net income $704M ($1.95/diluted share), non-GAAP $867M ($2.40).","Placed 427 da Vinci systems (240 da Vinci 5); installed base 10,763 (+13% YoY). Ion base 954 (+30%).","Repurchased 4.0M shares for $1.92B in Q3.","FY2025 guidance: procedure growth ~17-17.5%; non-GAAP gross margin 67-67.5% (incl. tariff impact ~0.7% of revenue)."],"consensus_eps_estimate":null,"consensus_eps_actual":5.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":7198500000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":133271,"accession_number":"0001035267-25-000183","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-07-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue up 21% to $2.44B; non-GAAP EPS $2.19 vs $1.78","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.44B (+21% YoY); GAAP diluted EPS $1.81; non-GAAP diluted EPS $2.19 (vs $1.46/$1.78 last year).","da Vinci procedures up ~17%; placed 395 systems including 180 da Vinci 5 (vs 341/70). Installed base 10,488 (+14% YoY).","Full-year 2025 guidance: procedure growth 15.5%-17%; non-GAAP gross margin 66%-67% (includes ~1% tariff impact).","EU MDR certification and Japan clearance obtained for da Vinci 5 in July/June 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":3.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":4693400000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149914,"accession_number":"0001035267-25-000161","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical promotes President Dave Rosa to CEO effective July 1, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["David J. Rosa promoted to CEO effective July 1, 2025; he previously served as President.","Current CEO Gary Guthart becomes Executive Chair; Board Chair Craig Barratt becomes Lead Independent Director.","Rosa's base salary increases from $825k to $925k; bonus target raised from 125% to 150% of salary.","Rosa receives RSUs valued at $4M and PSUs valued at $4M, vesting over 4 years and performance-based.","Guthart's base salary reduced to $700k; he will remain employee in senior advisory capacity."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149913,"accession_number":"0001035267-25-000156","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-05-05T23:59:59+00:00","items":["5.02","5.07","7.01","9.01"],"status":"ready","headline":"Intuitive Surgical boosts buyback to $4B; shareholders approve plan amendment increasing share reserve","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Board increased stock repurchase authorization to $4.0B aggregate, including prior remaining amounts.","Shareholders approved amendment to 2010 Incentive Award Plan: shares increased from 115.35M to 120.35M, term extended to 2035.","All 11 director nominees elected, including Gary Guthart, Craig Barratt, and Amy Ladd.","Advisory vote on executive compensation passed (273.6M for); two shareholder proposals (compensation, golden parachutes) rejected.","Ratification of PricewaterhouseCoopers as independent auditor for FY2025 (315.8M for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":149912,"accession_number":"0001035267-25-000106","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-04-22T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q1 revenue $2.25B, EPS $1.92; procedure volume +17%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.25B (+19% YoY); GAAP EPS $1.92, non-GAAP EPS $1.81.","da Vinci procedure volume +17% YoY; 367 systems placed (147 da Vinci 5).","Installed base 10,189 systems (+15% YoY).","FY25 outlook: procedure growth 15-17%; non-GAAP gross margin 65-66.5% (incl. ~1.7% tariff headwind).","Cash and investments $9.10B."],"consensus_eps_estimate":null,"consensus_eps_actual":1.92,"consensus_revenue_estimate":null,"consensus_revenue_actual":2253400000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168932,"accession_number":"0001035267-25-000008","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-23T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"Intuitive Q4 beats: rev $2.41B, adj EPS $2.21; buys Euro distributors for ~€321M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 da Vinci procedures grew ~18% YoY; 493 systems placed including 174 da Vinci 5.","Q4 GAAP EPS $1.88, non-GAAP EPS $2.21; revenue $2.41B (+25% YoY).","Acquisition of da Vinci/Ion distribution in Italy, Spain, Portugal, etc. for €290M upfront + €31M milestones; closing H1 2026.","2025 outlook: da Vinci procedure growth 13-16%, non-GAAP gross margin 67-68%.","Installed base grew 15% to 9,902 systems; cash and investments $8.83B."],"consensus_eps_estimate":null,"consensus_eps_actual":6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":8352100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168931,"accession_number":"0001035267-25-000005","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Q4 rev $2.41B (+25% YoY), procedures +18%; guides 2025 procedure growth 13-16%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 preliminary revenue $2.41B, up 25% YoY; full-year 2024 revenue $8.35B, up 17%.","Q4 da Vinci procedures grew ~18% YoY; full-year procedures up ~17% to 2,683,000.","493 da Vinci systems placed in Q4 (174 da Vinci 5), up 19% YoY; 1,526 in 2024, up 11%.","2025 procedure growth guidance of 13-16% vs 2024.","Q4 instruments & accessories revenue $1.41B (+23%), systems revenue $655M (+36%)."],"consensus_eps_estimate":null,"consensus_eps_actual":6.42,"consensus_revenue_estimate":null,"consensus_revenue_actual":8352100000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":168930,"accession_number":"0001035267-25-000002","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2025-01-06T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Intuitive Surgical promotes Samath to EVP/CFO and Charlton to EVP/Commercial","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Jamie Samath promoted to EVP, CFO and Head of Business Technology effective January 1, 2025.","Samath's base salary raised from $605k to $683k; bonus target increased from 65% to 100% of base.","Henry Charlton promoted to EVP, Chief Commercial and Marketing Officer effective same date.","Charlton's base salary raised from $600k to $670k; bonus target increased from 65% to 100% of base."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":186028,"accession_number":"0001035267-24-000244","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-10-17T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q3 revenue $2.04B (+17% YoY); GAAP EPS $1.56, non-GAAP $1.84","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["da Vinci procedures grew 18% YoY; placed 379 systems including 110 da Vinci 5 units.","Revenue $2.04B; instruments/accessories +18% to $1.26B; systems revenue $445M.","GAAP net income $565M ($1.56/diluted share) vs $416M ($1.16) in Q3 2023.","Non-GAAP net income $669M ($1.84/diluted share) vs $524M ($1.46).","South Korea regulatory clearance for da Vinci 5 in multiple surgical specialties."],"consensus_eps_estimate":null,"consensus_eps_actual":4.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":5938600000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202607,"accession_number":"0001035267-24-000215","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-07-25T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Intuitive President David J. Rosa appointed to Board of Directors, effective July 24, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Rosa has been Intuitive President since May 2023; manages core business operations including quality, regulatory, manufacturing, and commercial.","Board expanded from 11 to 12 directors; Rosa fills new seat, joining CEO Gary Guthart as the second executive on the board.","Rosa has over 27 years at Intuitive; also chairs Intuitive-Fosun joint venture board and serves on Kardium Inc. board.","No transactions requiring Item 404(a) disclosure were reported in connection with the appointment."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":202606,"accession_number":"0001035267-24-000203","cik":1035267,"company_name":"INTUITIVE SURGICAL INC","ticker":"ISRG","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Intuitive Surgical Q2 revenue $2.01B (+14% YoY), GAAP EPS $1.46, non-GAAP $1.78","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $2.01B (+14% YoY); GAAP net income $527M ($1.46 EPS), non-GAAP $641M ($1.78 EPS).","Worldwide da Vinci procedures grew ~17% vs Q2 2023; placed 341 systems (incl. 70 da Vinci 5).","Installed base grew 14% to 9,203 systems; instruments & accessories revenue $1.24B (+16%).","Cash and investments $7.68B, up $360M in quarter; no COVID disruption in H1 2024.","CEO cites healthy business, positive feedback on da Vinci 5 and adoption of SP and Ion."],"consensus_eps_estimate":null,"consensus_eps_actual":2.97,"consensus_revenue_estimate":null,"consensus_revenue_actual":3900500000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":148234862406.96338,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}